ProPhase Labs, Inc. Q3 FY2024 earnings call

• Capital raise to support aggressive launch of DNA Complete and DNA Expand for holiday sales, leveraging the gift-giving season.
• PMI is ramping up production with increased shifts, capacity, and new high-margin customers, with potential sale being explored.
• Plan to reduce overhead and expenses by at least $6 million, including satisfying payables, with anticipation of positive earnings swing.
• Accounts receivable from the government are a concern but optimistic about collection, though timing is uncertain.
• b Smart esophageal cancer test has significant market potential with a test to determine high/low risk of esophageal cancer, aiming for commercialization within next year.
• DNA Complete and DNA Expand launched with enhanced ancestry and health reports, targeting high-margin ancestry customers, and leveraging marketing expertise for efficient advertising.
• Equivir has promising clinical trial results, with preliminary data showing potential as a large-scale product.

Prophase Labs has multiple segments. Formalized manufacturing (PMI) is ramping up with increased capacity, new high-margin customers, and potential sale. DNA Complete and DNA Expand were recently launched, targeting the holiday season for sales with enhanced ancestry and more health reports. The b Smart esophageal cancer test has multibillion-dollar potential with a test to determine high/low risk of esophageal cancer. Nebula Genomics serves as the laboratory, and Prophase supplements include Legends XL and the upcoming Equivir with promising clinical trial results. Details on exact revenue contributions were not provided, but discussions focused on growth potential and ramping up of these segments.

• Anticipates Q4 strong performance with PMI expected to contribute $15 million+ in revenues and $5 million+ pretax profit, based on existing customers and capacity expansion.
• Plans to reduce overhead by year-end, expecting positive earnings swing from overhead reduction and earnings from formulas.
• Potential sale of PMI in first quarter with valuations up to $50 million, with future potential higher.
• Optimistic about b Smart test commercialization within next year, targeting a large market of endoscopies and potential reimbursement.

• Uncertainty in collecting accounts receivable from the government, impacting cash flow.
• Regulatory challenges for commercializing products like the b Smart test.
• Competition in the genomic and supplement markets, affecting market share.
• Dependence on holiday sales for DNA Complete and Expand success, with traction taking time.

Q: How is DNA Complete different from Nebula?

A: DNA Complete has enhanced ancestry and more health reports, separate from Nebula which is a lab; both are wholly owned subsidiaries of Prophase Labs with flexibility in lab usage.

Q: Can we expect initial sales figures for DNA Complete in Q4?

A: Likely to break out sales in Q4, but traction will take time, especially with the mid-November launch and holiday season ramp-up.

Q: What was the cost for launch/marketing for DNA Complete?

A: Work in progress, leveraging marketing expertise from Stu Hollinshead, focusing on efficient messaging and advertising to ensure positive return on investment.

Q: Any prospect to screen for more than just esophageal cancer for the b Smart test?

A: Focus on cost control, not developing new expensive initiatives; potential for other delivery methods but limited capital expenditure for new directions.

Q: Who were the shares in the financing sold to? How much stock did ThinkEquity get?

A: Investors are institutional clients of ThinkEquity, details not yet available as it's a standard investment banking deal.

Q: What is the basis of your forecast to do fifteen million and pretax profit of five million?

A: Based on existing high-margin customers, increasing prices, capacity expansion, and a new large customer taking all available capacity, with calculations on shifts, production, and costs.

Q: For the b Smart esophageal cancer test, could you provide more detail on partnerships?

A: Partnering with large cancer diagnostic companies, potential upfront and milestone payments, accelerating commercialization, with multiple multibillion-dollar companies interested in the test's IP